Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06160752 · ClinicalTrials.gov registry record · Phase 1
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
A Phase 1 study of Solid Tumor and Intrahepatic Cholangiocarcinoma, sponsored by Tyra Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 4
- Study locations
NCT06160752 is a Phase 1 study of Solid Tumor and Intrahepatic Cholangiocarcinoma that is actively recruiting participants, run by Tyra Biosciences. The registered enrollment target is 40 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (82% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT06160752, a Phase 1 study of Solid Tumor and Intrahepatic Cholangiocarcinoma, is actively recruiting participants, sponsored by Tyra Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-200 in cancers with FGFR2 activating gene alterations, including unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma and other advanced solid tumors.
Conditions Studied
Interventions
- DRUG Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles
- DRUG Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles
Study Locations (4)
California
- University of California San Francisco (UCSF) - San Francisco
Massachusetts
- Massachusetts General Hospital - Boston
Ohio
- The Ohio State University - Columbus
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-11-22 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06160752
The ClinicalTrials.gov registry entry for NCT06160752 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (82% lower). The listed sponsor is Tyra Biosciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles is the first listed.
NCT06160752 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Massachusetts, Ohio.
Frequently Asked Questions
What is clinical trial NCT06160752 about?
NCT06160752 is a clinical study titled "Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-200 in cancers with FGFR2 activating gene alterations, including unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma and other advanced solid tumo...
What is the current status of trial NCT06160752?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2023-11-22. Estimated completion is 2027-09.
What conditions does trial NCT06160752 study?
This clinical trial studies the following conditions: Solid Tumor, Intrahepatic Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Locally Advanced Cholangiocarcinoma.
What interventions are being tested in trial NCT06160752?
The interventions under investigation include: Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles (DRUG), Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles (DRUG).
Who is sponsoring clinical trial NCT06160752?
This trial is sponsored by Tyra Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06160752 being conducted?
This trial has 4 study locations across California, Massachusetts, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.